IL18 and lymphangioleiomyomatosis: In conclusion, our study described the differences in 59 immune-related factors between LAM and healthy subjects in a relatively large cohort and found that LAG-3 and IL-18 were likely biomarkers that can be used to diagnose and predict disease progression, respectively.